Mallinckrodt, Inc. designs, manufactures, and distributes respiratory care, imaging products, and prescription pharmaceuticals. It offers contrast media and delivery systems, radiopharmaceuticals, and urology imaging systems for the diagnosis and treatment of diseases in various imaging procedures. The company also provides peptide products, including amino acid derivatives and resins, as well as solid liquid phase peptides, and hybrid fragment synthesis; and active pharmaceutical ingredients and specialty generics. In addition, it offers respiratory products, including pulse oximetry systems, critical care ventilators, and endotracheal and tracheostomy tubes; personal oxygen systems; multiple CPAP sleep therapy products; sleep diagnostic systems to treat obstructive sleep apnea; and oral transmucosal fentanyl citrate, an opioid analgesic indicated for the management of cancer pain in patients with 16 years of age and older with malignancies. The company provides its products for hospitals, freestanding imaging centers, and nuclear pharmacies.